Burleson & Company LLC reduced its stake in Pfizer Inc. (NYSE: PFE – Get Rating) by 2.2% during the 1st quarter, according to the company in its latest 13F filing with the SEC. The company held 17,939 shares of the biopharmaceutical company after selling 410 shares during the quarter. Burleson & Company LLC’s holdings in Pfizer were worth $929,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also changed their positions in PFEs. Central Bank & Trust Co. increased its stake in Pfizer shares by 17.0% during the 4th quarter. Central Bank & Trust Co. now owns 24,163 shares of the biopharmaceutical company worth $1,427,000 after buying 3,518 additional shares in the last quarter. First Midwest Bank Trust Division increased its stake in Pfizer shares by 5.6% during the 4th quarter. The First Midwest Bank Trust division now owns 89,409 shares of the biopharmaceutical company worth $5,279,000 after buying 4,775 additional shares in the last quarter. HNP Capital LLC increased its stake in Pfizer shares by 12.0% during the 4th quarter. HNP Capital LLC now owns 18,221 shares of the biopharmaceutical company worth $1,076,000 after purchasing an additional 1,948 shares in the last quarter. Global Trust Asset Management LLC increased its stake in Pfizer shares by 4.9% during the 4th quarter. Global Trust Asset Management LLC now owns 58,988 shares of the biopharmaceutical company worth $3,483,000 after buying 2,776 additional shares in the last quarter. Finally, Crescent Capital Consulting LLC increased its stake in Pfizer shares by 11.9% during the 4th quarter. Crescent Capital Consulting LLC now owns 71,672 shares of the biopharmaceutical company worth $4,235,000 after purchasing an additional 7,627 shares in the last quarter. Institutional investors hold 66.50% of the company’s shares.
NYSE:PFE opened at $53.17 on Monday. The company has a 50-day moving average of $50.98 and a 200-day moving average of $51.79. The company has a market capitalization of $298.33 billion, a price-earnings ratio of 12.19, a PEG ratio of 0.64 and a beta of 0.73. Pfizer Inc. has a 52-week low of $39.46 and a 52-week high of $61.71. The company has a debt ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39.
Pfizer (NYSE:PFE – Get Rating) last released its quarterly earnings data on Tuesday, May 3. The biopharmaceutical company reported EPS of $1.62 for the quarter, missing analyst consensus estimates of $1.66 per ($0.04). The company posted revenue of $25.66 billion for the quarter, versus a consensus estimate of $24.73 billion. Pfizer had a return on equity of 38.29% and a net margin of 26.97%. Pfizer’s revenue increased 76.8% year over year. In the same period a year earlier, the company posted earnings per share of $0.93. Sell-side analysts expect Pfizer Inc. to post EPS of 6.63 for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6. Shareholders of record on Wednesday, June 29 will receive a dividend of $0.40 per share. This represents a dividend of $1.60 on an annualized basis and a dividend yield of 3.01%. The ex-dividend date is Thursday July 28. Pfizer’s payout ratio is 36.70%.
Several analysts have recently released reports on PFE shares. JPMorgan Chase & Co. set a price target of $57.00 on Pfizer shares in a Tuesday, June 28 report. Citigroup raised its price target on Pfizer shares from $46.00 to $57.00 and gave the stock a “neutral” rating in a Tuesday, April 5 report. SVB Leerink began covering Pfizer shares in a Monday, May 23 report. They set a “market performance” rating and a price target of $55.00 for the company. Berenberg Bank set a price target of $50.00 on Pfizer shares in a Friday, May 27 report. Finally, Barclays set a price target of $52.00 on Pfizer shares in a report on Thursday. Nine equity research analysts gave the stock a hold rating, ten issued a buy rating and one gave the company’s stock a high buy rating. Based on MarketBeat data, Pfizer currently has an average rating of “Moderate Buy” and a consensus price target of $56.95.
Separately, Executive Vice President William R. Carapezzi, Jr. sold 32,908 shares in a trade dated Thursday, May 12. The shares were sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the completion of the sale, the executive vice president now owns 38,146 shares of the company, valued at approximately $1,907,300. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. Additionally, SVP Jennifer B. Damico sold 4,218 shares in a trade dated Tuesday, June 7. The stock was sold at an average price of $53.96, for a total transaction of $227,603.28. Following the sale, the senior vice president now owns 10,846 shares of the company, valued at approximately $585,250.16. The disclosure of this sale can be found here. Insiders sold a total of 41,126 shares of the company valued at $2,075,003 during the last quarter. 0.05% of the shares are currently held by insiders.
Pfizer profile (Get a rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes and sells biopharmaceuticals worldwide. It offers drugs and vaccines in various therapeutic areas, including cardiovascular, metabolic and women’s health under the Premarin Family and Eliquis brands; biologics, small molecules, immunotherapies and biosimilars under the brands Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena and Braftovi; and sterile injectable and anti-infective drugs, and oral treatment for COVID-19 under the brands Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga and Paxlovid.
Want to see which other hedge funds hold PFEs? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Pfizer Inc. (NYSE:PFE – Get Rating).
Get news and reviews for Pfizer Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.